Antibiotic Prophylaxis for Prevention against Lyme Disease Following Tick Bite: An Updated Systematic Review and Meta-Analysis

Guozhong Zhou
Kunming Medical University

Xin Xu
Kunming Medical University

Yu Zhang
Kunming Medical University

Peng Yue
Kunming Medical University

Shiqi Luo
Kunming Medical University

Yuxin Fan
Kunming Medical University

Jingjing Chen
Kunming Medical University

Meixiao Liu
Kunming Medical University

Yan Dong
Kunming Medical University

Bingxue Li
Kunming Medical University

Jing Kong
Kunming Medical University

Shiyuan Wen
Kunming Medical University

Aihua Liu
Kunming Medical University

Fukai Bao (baofukai@kmmu.edu.cn)
Kunming Medical University

Research Article

Keywords: Borrelia burgdorferi, borreliosis, Ixodes, Lyme disease, tick bite

DOI: https://doi.org/10.21203/rs.3.rs-562517/v1
Abstract

**Background:** In areas where Lyme disease is endemic, bites from ticks are common, but no vaccine is currently available against Lyme disease for humans. Therefore, the feasibility of using antibiotic prophylaxis to prevent Lyme disease after a tick bite is worth further exploration. Previous meta-analyses lack sufficient power to demonstrate the efficacy of antibiotic prophylaxis for the prevention of Lyme disease following a tick bite. In this study, we explored more precise evidence and attempted to identify and update optimum treatment strategies.

**Methods:** We searched PubMed, Embase, and the Cochrane Library for studies until March 23, 2021. We included studies if the enrolled patients were randomly allocated to a treatment or control group within 72 h following a tick bite and had no clinical evidence of Lyme disease at enrolment. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for data abstraction. Two authors (GZZ and XX) independently reviewed the abstracts and identified articles for detailed assessment. We used a random-effects model to calculate the pooled results and reported the 95% confidence interval (CI). Study quality was assessed using a modified Jadad scale, and publication bias was assessed using Egger's test. We calculated the risk ratio (RR) for the rates of unfavorable events in patients who received intervention versus the control group. This study is registered with PROSPERO, number CRD42021245002

**Results:** Six studies (3,766 individuals) were included. The pooled rate of unfavorable events in persons receiving treatment and the control group were 0.4% (95%CI: 0.1–1.1%) and 2.2% (95%CI: 1.6–3.0%), respectively. The pooled RR was 0.38 (95%CI: 0.22–0.66). Subgroup analysis revealed that the pooled RR was 0.29 (95%CI: 0.14–0.60) in the single-use 200-mg doxycycline group; 0.28 (95%CI: 0.05–1.67) in a 10-day course group (Amoxicillin, Penicillin or tetracycline); and 0.73 (95%CI: 0.25–2.08) in a topical antibiotic treatment group (Azithromycin).

**Conclusions:** The available evidence supports the use of antibiotics for the prevention of Lyme disease, and reveals advantages of using single-dose; however, further confirmation is needed.

Introduction

Lyme disease is the most common tick-borne disease in the northern hemisphere and is caused by the spirochetes *Borrelia burgdorferi* (*B. burgdorferi*) [1]. The United States has an estimated 300,000 cases of Lyme disease annually [2], and 65,500–85,000 cases are reported annually in Europe [3]. Early manifestations of Lyme disease include non-specific signs and symptoms such as fever, headache, and myalgias [4]. With appropriate and prompt antibiotic treatment, most patients recover from Lyme disease without complications. However, up to 20% of patients may develop chronic subjective symptoms, collectively known as post-treatment Lyme disease syndrome; these include pain and swelling in the joints, problems affecting the nervous system, and cardiac problems [5].

In areas where Lyme disease is endemic, bites from ticks are common. For instance, 25–30% of people from endemic areas in the United States have reported that a member of the household was bitten by a tick in the preceding year [6]. However, no vaccine for humans is yet available against Lyme disease [7, 8]. Therefore, the feasibility of using antibiotic prophylaxis to prevent Lyme disease following a tick bite is worth further investigation. However, in the past three decades, there have been some controversies over antibiotic prophylaxis to prevent Lyme disease following a tick bite [9–13], and the recommendation of guidelines were conflicting [14].
In 2006 [15], guidelines from the Infectious Diseases Society of America (IDSA) stated that a single dose of 200 mg doxycycline may be offered to adult patients. In 2014 [16], guidelines from the International Lyme and Associated Diseases Society (ILADS) advised against the single 200 mg dose of doxycycline, but recommended prompt prophylaxis with doxycycline 100–200 mg twice daily for a minimum of 20 days for all *Ixodes* tick bites in which there is evidence of tick feeding, regardless of the degree of tick engorgement or the infection rate in the local tick population. In 2019 [7], guidelines from French Scientific Societies stated that initiating an antibiotic therapy is not recommended, irrespective of the patient's age, duration of tick attachment, and the stage of development of the extracted tick. In 2020 [17], guidelines from IDSA, American Academy of Neurology (AAN), and American College of Rheumatology (ACR) recommended the administration of a single dose of oral doxycycline within 72 h of tick removal and observation in all age groups.

In 1996, Warshafsky et al. published a meta-analysis including three studies and found that the efficacy of antibiotic prophylaxis for prevention of Lyme disease was uncertain, as the 95% confidence interval (CI) was wide [18]. In 2010, Warshafsky et al. updated the meta-analysis, which added one new study into the statistical analysis, and reported that antibiotic prophylaxis was effective for prevention of Lyme disease following a tick bite [19]. However, only 1,082 subjects were included and unfavorable events were scarce in the meta-analysis. Moreover, the efficacy of different treatment strategies could not be assessed. To address these inconsistencies, we performed this updated meta-analysis and explored more precise evidence for an in-depth assessment of the efficacy of antibiotic prophylaxis for prevention of Lyme disease, and attempted to identify the preferred treatment strategy.

**Methods**

**Search strategy**

We adhered to the PRISMA guidelines for conducting the present meta-analysis, and it was registered in PROSPERO (CRD42021245002). We identified eligible studies by searching PubMed, EMBASE, and the Cochrane Library. We collected studies from the earliest available date, i.e., January 1, 1962 to March 23, 2021. As mentioned in Warshafsky et al’ study [19], the following keyword combinations were used: “(Lyme or borreliosis) and (prophylaxis or prevention),” without language restrictions. To minimize publication bias, we retrieved the reference lists of included studies and manually searched for other relevant studies that met our inclusion criteria.

**Selection criteria**

All studies in which the enrolled patients were randomly allocated to a treatment or control group, were enrolled within 72 h following an *Ixodes* tick bite, and had no clinical evidence of Lyme disease at enrolment were included in our analysis. There were no restrictions based on the antibiotics used, age of the enrolled patients, length of patient follow-up, or the observed outcomes. All included studies were assessed independently by two authors (GZZ and XX). Disagreement for a particular assessment was resolved by discussing the issues with the third partner until a consensus was reached.

**Data extraction**
The two authors (GZZ and XX) independently reviewed the abstracts and identified articles for detailed assessment. Disagreement for a particular assessment was resolved by discussing the issues until a consensus was reached. The form included a fixed set of fields: title, author, year of publication, country or area, patient demographics, antibiotics used, daily dose of antibiotics, duration of therapy, duration of follow-up, number of patients in the antibiotic-treatment group and control group, and the number of unfavorable events in each study group. As mentioned in Warshafsky et al’ study [19], an unfavorable event was defined as the development of erythema migrans at the site of the tick bite or an objective manifestation compatible with early extracutaneous Lyme disease (e.g., seventh cranial nerve palsy) or late Lyme disease (e.g., arthritis) confirmed by seroconversion.

Quality assessment

We appraised the quality of studies by using a modified Jadad Scale, which included four parts: randomization, with scores ranging from 0 to 2; concealment of allocation, with scores ranging from 0 to 2; double blinding, with scores ranging from 0 to 2; withdrawals and dropouts, with scores ranging from 0 to 1. Studies with a Jadad score between 1 and 3 was considered low quality, while that with a score between 4 and 7 was considered high quality. The quality of all studies was assessed independently by the same two authors (GZZ and XX). As mentioned, any disagreement was resolved by detailed discussion until consensus was achieved.

Statistical analysis

We calculated the risk ratio (RR) for the rates of unfavorable events in patients who received intervention versus the control group. Results from studies were grouped according to the treatment strategy of antibiotics, and we also conducted a sensitivity analysis to assess the robustness of results. We used Cochran’s Q test and Higgins I² statistic to assess the heterogeneity of the included studies. We used a random-effects model to calculate the pooled results and the 95% CI. A p-value<0.10 or a I² value>50% suggested significant heterogeneity. Egger’s test was used to detect publication bias, and a p-value<0.10 on Egger’s test was considered indicative of statistically significant publication bias. This meta-analysis was conducted using the “meta” package in R statistical software version 3.4.3 (Schwarzer, 2007; Team, 2017).

Results

Initially, 4,515 studies were identified and 4,509 were excluded after screening the titles and abstracts, as well as the full texts of all articles according to the inclusion criteria.

Six randomized controlled trials (RCTs) [3,9,20-23] met the inclusion and exclusion criteria and were eligible for the final analysis. The selection process is shown in Figure 1. The characteristics of the included studies are shown in Table 1, and the quality assessment performed by Jadad Scale is shown in Table 2.

Our meta-analysis included six articles and a total of 3,766 participants. The sample sizes of the studies ranged from 56 to 1,689 subjects. Meta-analysis showed that the pooled rates of unfavorable events in patients who received intervention and control groups were 0.4% (95%CI: 0.1–1.1%, I²=55%) and 2.2% (95%CI: 1.6–3.0%, I²=5%), respectively. The pooled RR was 0.38 (95%CI: 0.22–0.66, I²=0%) (Table 3 and Figure 2).

Oral antibiotic therapy was administered in five studies, and the pooled rate of unfavorable events in patients who received intervention and control groups were 0.2% (95%CI: 0.0–1.0%, I²=57%) and 2.5% (95%CI: 1.7–3.5%,
I^2=0\%\), respectively. The pooled RR was 0.29 (95\%CI: 0.15–0.57, I^2=0\%) (Table 3). Of these five studies, a 10-day course of antibiotic treatment was administered in three studies, and the pooled rate of unfavorable events in patients who received intervention and control groups were 0.0\% (95\%CI: 0.0–0.3\%, I^2=0\%) and 1.3\% (95\%CI: 0.3–2.9\%, I^2=0\%), respectively. The pooled RR was 0.28 (95\%CI: 0.05–1.67, I^2=0\%). A single-dose 200-mg doxycycline therapy was administered in the remaining two studies, and the pooled rates of unfavorable events in persons with intervention and control groups were 0.8\% (95\%CI: 0.4–1.4\%, I^2=0\%) and 3.0\% (95\%CI: 2.0–4.2\%, I^2=0\%), respectively. The pooled RR was 0.29 (95\%CI: 0.14–0.60, I^2=0\%).

The results of sensitivity analysis showed that the confidence interval of the pooled RR became imprecise when Harm et al’s study [9] was excluded (Figure 3). Egger’s test was used to assess for any publication bias among the six studies, and no evidence of publication bias was found in this review (p=0.515).

**Discussion**

Our study included more participants than a previous meta-analysis [19] (3,766 vs. 1,082), and strengthened the evidence that prophylactic antibiotic use is effective for the prevention of Lyme disease following a tick bite. Furthermore, our subgroup analysis revealed that patients who received a single dose (200 mg) course were shown to be less likely to develop Lyme disease than those given placebo (RR, 0.29 [95\%CI: 0.14–0.60]), but there is no evidence of the effectiveness of a 10-day course and topical antibiotics course (RR, 0.28 [95\%CI: 0.05–1.67] and 0.73 [95\%CI: 0.25–2.08]), respectively. Our results support the strategy of a single-dose oral doxycycline therapy for prevention of Lyme disease.

As early as 2001, Nadelman et al. assessed the effect of doxycycline in the prevention of Lyme disease. However, the effectiveness estimated in the RCTs showed a wide confidence interval (RR = 0.13 [0.02–1.04]) [23]. Until recently, an RCT [9] with a relatively large sample size (n = 1,089) provided stronger evidence that a single dose of doxycycline can prevent the development of Lyme disease, following a bite from *Ixodes ricinus* (RR = 0.33 [0.15–0.70]). Our meta-analysis combined two RCTs and showed a more accurate CI (RR = 0.29 (0.14–0.60)). Additionally, two observational studies reported the results of doxycycline in the prevention of Lyme disease. Korenberg et al. [24] reported that none of the patients in the experimental group (n = 261) developed erythema migrans after receiving doxycycline (100 mg twice daily) for 3–5 days after the tick bite, whereas 5/97 patients developed erythema migrans in the control group which did not receive any antibiotics. Jackson et al. [25] reported the clinical application of doxycycline for Lyme disease prophylaxis, and the results indicated a high level of satisfaction with the pharmacy services provided, with no reports of subsequent development of Lyme disease symptoms or other side effects. However, the sample size of this study was small (n = 8).

Although our results support the use of antibiotics for the prevention of Lyme disease and the advantages of a single dose of doxycycline, routine use of antibiotic prophylaxis is not recommended after a recognized tick bite [17]. In our meta-analysis, we estimated that 50 patients (95\%CI: 25–100) would need to be treated (NNT) with single-dose doxycycline to prevent one case of Lyme disease. The main reason of the high NNT is that only a few people who have been bitten develop Lyme disease, even without antibiotic prophylaxis. In fact, the risk of developing Lyme disease after a tick bite is < 5\% even in high-endemicity areas [7]. Therefore, it is essential to
determine who is at high risk of infection and who is worthy of treatment. For instance, a previous study found that if the tick attachment time is more than 36 h, the local rate of tick infection with*B. burgdorferi* is at least 20% [14, 15]. Consequently, guidelines state that a tick bite is considered to be high-risk only if it was attached for more than 36 h [16]. Falco et al. reported that at least 43.5% of all tick bites had been attached for <36 h [26], so the recommendation represents that nearly half of patients avoid receive antibiotics treatment. Additionally, Mladenović et al. [27] found that improper tick removal increased the risk of Lyme disease as compared with correct tick removal (RR = 23.55). Nadelman et al [23] found that erythema migrans developed more frequently after bites from nymphal ticks than after bites from adult ticks, with an incidence rate of 5.6% and 0%, respectively. Harms et al [9], revealed that 11.1% untreated patients with a *B. burgdorferi*-positive tick bite developed Lyme disease, and the NNT in this subgroup was only 10. These findings might provide valuable information for clinicians, but need further confirmation.

Antibiotic use has some side effects [13]. The major side effects of oral doxycycline include enterocolitis, anaphylaxis (including angioedema), Stevens–Johnson syndrome, severe urticarial reactions, and a lupus-like syndrome. Minor reactions of intravenous ceftriaxone include gastrointestinal symptoms of abdominal pain, nausea, vomiting, and diarrhea, and hypersensitivity reactions such as rash, pruritus, fever and chills, candidiasis, and local reactions at the injection site [14]. Although none of included studies reported serious side effects, there were still many minor side effects reported such as rash or nausea. The two studies revealed that incidence of mild side effects after using single-dose doxycycline was 5.9–30.1% [9, 23], which suggests that up to a third of patients are likely to suffer mild side effects. Availability of a universally acceptable and effective prophylactic agent with minimal side effects would be the ideal. Previous studies found that topical azithromycin was highly effective when applied topically at the sites of tick bites in mice [28, 29]. Although no effective evidences were found in human trials [3], a topical pharmacological prophylactic strategy is still worth exploring [30], given that minor side effects such as localized itching, redness, and dryness were reported only in 1.6% patients [3].

Our meta-analysis has some limitations. First, although we screened more than 4,000 related articles, only six studies were eligible for final analysis. Second, Harm et al’s study [9], which included 1689 participants, contributed 54.5% of the weight to the pooled results, but this study was the only one assessed as low quality (Jadad score 3). Therefore, our evidence is limited and further confirmation is needed. Third, of the 56 unfavorable events in our meta-analysis, 55 were erythema migrans, and only one was disseminated Lyme disease. Therefore, more reliable evidence is required from studies with longer follow-up time in future. Last, we did not analyze the seroconversion results, because only few patients showed seroconversion even in the control group.

**Conclusion**

The available evidence supports the prophylactic use of antibiotics for the prevention of Lyme disease and the advantages of a single dose of doxycycline, but further confirmation is needed.

**Abbreviations**

*B. Burgdorferi*: *Borrelia burgdorferi*; CI: confidence interval; RR: risk ratio; RCTs: randomized controlled trials; NNT: need to be treated.
Declarations

Acknowledgements

Not applicable.

Authors' contributions

GZZ, FKB and AHL conceived the study and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. GZZ and XX did the literature search, selected the studies, extracted the relevant information and synthesized the data. YZ, YP and SQL developed the protocol. GZZ completed the analysis and maintained the database. GZZ, FKB and AHL wrote the first draft of the paper and all authors critically revised successive drafts of the paper and approved its final version.

Funding

This work was supported by National Natural Science Foundation of China grants 31560051, 81560596, and 81860644, and Natural Foundation of Yunnan Province grants 2019FE001-(002) and 2017FE467-(001). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not required.

Consent for publication

Not applicable.

Competing interests

None of the authors in this study have any conflict of interest regarding the publication of the paper.

Author details

1 The Institute for Tropical Medicine, School of Basic Medical Sciences, Kunming Medical University, Kunming, China. 2 Yunnan Province Key Laboratory for Tropical Infectious Diseases in Universities, Kunming Medical University, Kunming, China.

References
1. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. *Nat Rev Dis Primers.* 2016;2:16090. doi: 10.1038/nrdp.2016.90

2. Nelson CA, Saha S, Kugeler KJ, et al. Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010. *Emerg Infect Dis.* 2015;21(9):1625–1631. doi: 10.3201/eid2109.150417

3. Schwameis M, Kündig T, Huber G, et al. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial. *Lancet Infect Dis.* 2017;17(3):322–329. doi: 10.1016/S1473-3099(16)30529-1

4. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease—United States, 1992–2006. *MMWR Surveill Summ.* 2008;57(10):1–9. https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5710a1.htm

5. Feng J, Li T, Yee R, et al. Stationary phase persister/biofilm microcolony of *Borrelia burgdorferi* causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. *Discov Med.* 2019;27(148):125–138. https://www.discoverymedicine.com/Jie-Feng/2019/03/persister-biofilm-microcolony-borrelia-burgdorferi-causes-severe-lyme-arthritis-in-mouse-model/

6. Hook SA, Nelson CA, Mead PS. U.S. public’s experience with ticks and tick-borne diseases: Results from national Health Styles surveys. *Ticks Tick Borne Dis.* 2015;6(4):483–488. doi: 10.1016/j.ttbdis.2015.03.017

7. Figoni J, Chirouze C, Hansmann Y, et al. Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosis. *Med Mal Infect.* 2019;49(5):318–334. doi: 10.1016/j.medmal.2019.04.381

8. Richardson M, Khouja C, Sutcliffe K. Interventions to prevent Lyme disease in humans: A systematic review. *Prev Med Rep.* 2019;13:16–22. doi: 10.1016/j.pmedr.2018.11.004

9. Harms MG, Hofhuis A, Sprong H, et al. A single dose of doxycycline after an *Ixodes ricinus* tick bite to prevent Lyme borreliosis: An open-label randomized controlled trial. *J Infect.* 2021;82(1):98–104. doi: 10.1016/j.jinf.2020.06.032

10. Wormser GP, Warshawsky S, Visintainer P. Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever. *Diagn Microbiol Infect Dis.* 2021;99(4):115293. doi: 10.1016/j.diagmicrobio.2020.115293

11. D'Alessandro M, Loy A, Castagnola E. Management of Lyme Disease in European Children: a Review for Practical Purpose. *Curr Infect Dis Rep.* 2017;19(8):27. doi: 10.1007/s11908-017-0582-9.

12. Ogden NH, Lindsay LR, Schofield SW. Methods to Prevent Tick Bites and Lyme Disease. *Clin Lab Med.* 2015 Dec;35(4):883 – 99. doi: 10.1016/j.cll.2015.07.003

13. Wormser GP. Doxycycline for Prevention of Spirochetal Infections: Status Report. *Clin Infect Dis.* 2020;71(8):2014–2017. doi: 10.1093/cid/ciaa240

14. Sutton DS, Spry C. One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;2019. https://www.ncbi.nlm.nih.gov/books/NBK545493/

15. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis.* 2006;43(9):1089–1134. doi: 10.1086/508667
16. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. *Expert Rev Anti Infect Ther.* 2014;12(9):1103–1135. doi: 10.1586/14787210.2014.940900

17. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. *Clin Infect Dis.* 2021;72(1):1–8. doi: 10.1093/cid/ciab049

18. Warshafsky S, Nowakowski J, Nadelman RB, Kamer RS, Peterson SJ, Wormser GP. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. *J Gen Intern Med.* 1996;11(6):329–33. doi: 10.1007/BF02600042

19. Warshafsky S, Lee DH, Francois LK, Nowakowski J, Nadelman RB, Wormser GP. Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis. *J Antimicrob Chemother.* 2010;65(6):1137–1144. doi: 10.1093/jac/dkq097

20. Costello CM, Steere AC, Pinkerton RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. *J Infect Dis.* 1989;159(1):136–139. doi: 10.1093/infdis/159.1.136

21. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. *N Engl J Med.* 1992;327(25):1769–1773. doi: 10.1056/NEJM199212173272501

22. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. *Am J Dis Child.* 1993;147(9):945–947. doi: 10.1001/archpedi.1993.02160330035013

23. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N Engl J Med.* 2001;345(2):79–84. doi: 10.1056/NEJM200107123450201

24. Korenberg EI, Vorobyeva NN, Moskvitina HG, LyA G. Prevention of borreliosis in persons bitten by infected ticks. *Infection.* 1996;24(2):187-9. doi: 10.1007/BF01713337

25. Jackson AN, Orr KK, Bratberg JP, Silverblatt F. Pharmacist initiation of postexposure doxycycline for Lyme disease prophylaxis. *J Am Pharm Assoc* (2003). 2014;54(1):69–73. doi: 10.1331/JAPhA.2014.13106

26. Falco RC, Daniels TJ, Vinci V, McKenna D, Scavarda C, Wormser GP. Assessment of Duration of Tick Feeding by the Scutal Index Reduces Need for Antibiotic Prophylaxis After *Ixodes scapularis* Tick Bites. *Clin Infect Dis.* 2018;67(4):614–616. doi: 10.1093/cid/ciy221

27. Mladenović J, Cekanac R, Stajković N, Krstić M. Risk of Lyme disease development after a tick bite. *Vojnosanit Pregl.* 2010;67(5):369–374. doi: 10.2298/vsp1005369m

28. Knauer J, Krupka I, Fueldner C, Lehmann J, Straubinger RK. Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model. *J Antimicrob Chemother.* 2011;66(12):2814–2822. doi: 10.1093/jac/dkr371

29. Piesman J, Hojgaard A, Ullmann AJ, Dolan MC. Efficacy of an experimental azithromycin cream for prophylaxis of tick-transmitted Lyme disease spirochete infection in a murine model. *Antimicrob Agents Chemother.* 2014;58(1):348–351. doi: 10.1128/AAC.01932-13

30. Jin N, Pyo SM, Keck CM, Müller RH. Azithromycin nanocrystals for dermal prevention of tick bite infections. *Pharmazie.* 2019;74(5):277–285. doi: 10.1691/ph.2019.8169
### Table 1. Characteristics of randomized clinical trials included in meta-analysis

| Area                  | Age                      | Males (%) | Antibiotic       | Oral or topical | Daily dose (mg) | Duration (d) | Follow-up (m) |
|-----------------------|--------------------------|-----------|------------------|-----------------|-----------------|--------------|---------------|
| Costello et al 1989   | USA                      | Adults and children | 35.7            | Penicillin      | Oral            | 1000         | 10            |
| Shapiro et al 1992    | USA                      | Adults and children | 42.6            | Amoxicillin     | Oral            | 750          | 10            |
|                       |                          |           |                  |                 |                 |              | $^b$12        |
| Agre et al 1993       | USA                      | Children  | 49.2             | Penicillin or tetracycline$^a$ | Oral            | 1000         | 10            |
|                       |                          |           |                  |                 |                 |              | 12-36         |
| Nadelman et al 2001   | USA                      | Adults and children | 53.3            | Doxycycline     | Oral            | 200          | 1             |
|                       |                          |           |                  |                 |                 |              | 1.5           |
| Schwameis et al 2016  | Germany and Austria      | Adults    | 48.7             | Azithromycin    | Topical         | -            | 3             |
|                       |                          |           |                  |                 |                 |              | 2             |
| Harms et al 2021      | Netherlands              | Adults and children | 50.0            | Doxycycline     | Oral            | 200          | 1             |
|                       |                          |           |                  |                 |                 |              | 6             |

$^a$ Patients older than 9 years received tetracycline and those younger than 9 years received penicillin.

$^b$ Visit follow-up for 3 months, and telephone follow-up for 12 months.

### Table 2. Quality assessment performed by Jadad Scale of included studies

|                      | Costello et al 1989 [11] | Shapiro et al 1992 [12] | Agre et al 1993 [13] | Nadelman et al 2001 [14] | Schwameis et al 2016 [3] | Harms et al 2021 [15] |
|----------------------|--------------------------|--------------------------|-----------------------|--------------------------|--------------------------|-----------------------|
| Randomization        | 1                        | 2                        | 2                     | 2                        | 2                        | 2                     |
| Concealment of allocation | 2                   | 2                        | 2                     | 2                        | 2                        | 0*                    |
| Double blinding      | 2                        | 2                        | 2                     | 2                        | 2                        | 0*                    |
| Withdrawals and dropouts | 1                   | 1                        | 1                     | 0                        | 1                        | 1                     |
| Total Jadad quality score | 6                     | 7                        | 7                     | 6                        | 7                        | 3                     |
*Controls did not receive any treatment including placebo, so concealment of allocation and double blinding could not be achieved.

Table 3. Main outcomes measures, for total calculation and subgroups

|                        | Studies (n) | Participants (n) | Rate in intervention (%) | I² (%) | Participants (n) | Rate in control (%) | I² (%) | Risk ratio | I² (%) |
|------------------------|-------------|------------------|--------------------------|--------|------------------|---------------------|--------|------------|--------|
| Oral treatment         | 5           | 1584             | 0.2 (0.0–1.0)            | 57     | 1187             | 2.5 (1.7–3.5)       | 0      | 0.29       | 0      |
| 10-day course          | 3           | 308              | 0.0 (0.0–0.3)            | 0      | 292              | 1.3 (0.3–2.9)       | 0      | 0.28       | 0      |
| Single dose            | 2           | 1276             | 0.8 (0.4–1.4)            | 0      | 895              | 3.0 (2.0–4.2)       | 0      | 0.29       | 0      |
| Topical treatment      | 1           | 505              | 1.2 (0.4–2.3)            | N/A    | 490              | 1.6 (0.7–2.9)       | N/A    | 0.73       | N/A    |
| Total                  | 6           | 2089             | 0.4 (0.1–1.1)            | 55     | 1677             | 2.2 (1.6–3.0)       | 5      | 0.38       | 0      |

Figures
Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flowchart of study selection process.
Figure 2

Forest plot of the risk ratio for incidence rates of Lyme disease, with antibiotic groups versus control groups

Figure 3

The sensitivity analysis of the six included studies